D-1342-2020 Class III Terminated
FDA drug recall D-1342-2020 was initiated by Pfizer Inc. on May 27, 2020 and is designated Class III. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Jun 30, 2023). Affected quantity: 544400 packages.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 1, 2020
- Initiation Date
- May 27, 2020
- Termination Date
- Jun 30, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 544400 packages
Product description
Duavee (conjugated estrogens/bazedoxifene) tablets 0.45/20 mg, packaged in 2 blister cards containing 15 tablets each (30 tablets), Rx Only, Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer In Philadelphia, PA 19101 Made in Ireland, NDC 00008-1123-12
Reason for recall
Failed Dissolution Specifications
Distribution pattern
Nationwide within the United States
Code information
Lot #: AF7814, 2021 AUG 31; AH6565, 2021 SEP 30, AP5189, 2020 SEP30; CG8921, 2022 FEB 28; CL6603, DH5847, 2022 MAR 31; T17703, T99214 2020 JUN 30, W46878, X07330, 2020 SEP 30; X99074, 2021 JUN 30
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1342-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026